Strategic Partners A/S

Strategic Partners A/S Net Debt/FCF

The Net Debt to Free Cash Flow Ratio of Strategic Partners A/S (STRAP.CO) as of Nov 16, 2026 is 0.10. In the previous year, Net Debt to Free Cash Flow Ratio was 1.21 — a change of -91.44% (lower).

Net Debt/FCF

0.10

YoY

-91.44%

Last updated:

Net Debt to Free Cash Flow Ratio of Strategic Partners A/S is 2021 0.10 . Net Debt to Free Cash Flow Ratio of Strategic Partners A/S was 2020 1.21 . It decreases by -91.44% lower compared to the previous year.

The Strategic Partners A/S Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2014
2.11 DKK
Jan 1, 2015
1.44 DKK
Jan 1, 2019
0.14 DKK
Jan 1, 2020
1.21 DKK
Jan 1, 2021
0.10 DKK
The Strategic Partners A/S Net Debt/FCF history
YEARNet Debt/FCFYoY
0.10-91.44%
1.21+756.43%
0.14-90.25%
1.44-31.40%
2.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Orphazyme A/S develops treatments for rare genetic disorders, focusing on lysosomal storage diseases and protein aggregation diseases. The company's main product, arimoclomol, works by stimulating heat shock proteins to help misfolded proteins either refold correctly or be removed via lysosomes. Orphazyme collaborates with academic institutions in Europe and the United States to advance its preclinical development efforts. The company generates revenue through partnerships and collaborations with academic institutions for the development of its therapies. These partnerships support the preclinical research phase of arimoclomol, which targets approximately 50 genetic disorders known as lysosomal storage diseases. Orphazyme's focus remains on advancing its pipeline of treatments for life-threatening and debilitating rare diseases. Orphazyme A/S serves the medical research and pharmaceutical sectors by providing innovative therapeutic approaches for rare diseases. Its target market includes patients with lysosomal storage diseases and protein aggregation disorders, who face significant health challenges due to genetic deficiencies. The company's work aims to address unmet medical needs in these rare disease areas. Strategic Partners A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strategic Partners A/S stock

Net Debt to Free Cash Flow Ratio of Strategic Partners A/S is 0.10 in 2021.

Net Debt to Free Cash Flow Ratio of Strategic Partners A/S changed from 1.21 to 0.10, representing a -91.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's Strategic Partners A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Strategic Partners A/S

All Key Metrics — Strategic Partners A/S